Implantable Infusion Pump MarketThe global implantable infusion pump market is set to witness significant growth, with an expected valuation of approximately USD 485.1 million in 2022. The market is ...

Analyst Jeff Johnson from Robert W. Baird reiterated a Hold rating on Tandem Diabetes Care (TNDM – Research Report) and increased the ...

GAMMA Investing LLC increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 17.0% ...

Fintel reports that on October 4, 2024, Goldman Sachs initiated coverage of Tandem Diabetes Care (NasdaqGM:TNDM) with a ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...

RBC expects 51% gross margins in 2024, with the Mobi pump launch driving long-term profitability. RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. TNDM, a global insulin ...

slim X2 pump, to be used in the 27-country bloc to deliver Eli Lilly's Lyumjev ultra-rapid acting insulin. Before you buy stock in Tandem Diabetes Care, consider this: The Motley Fool Stock ...

Despite that, it remains bullish on Tandem's prospects ... the company's t:slim X2 pump, to be used in the 27-country bloc to deliver Eli Lilly's Lyumjev ultra-rapid acting insulin.

Tandem Diabetes Care TNDM has achieved a significant milestone by gaining approval for the use of its t:slim X2 insulin pump with Eli Lilly’s ultra-rapid acting insulin, Lyumjev, in the European ...

Your bid or registration is pending approval with the auctioneer. Please check your email account for more details. Unfortunately, your registration has been declined by the auctioneer. You can ...

Tandem Diabetes Care TNDM has achieved a significant milestone by gaining approval for the use of its t:slim X2 insulin pump with Eli Lilly’s ultra-rapid acting insulin, Lyumjev, in the European Union ...